Andy Qingan Yuan

Andy Qingan Yuan

Auto-generated profile, based on publicly available information

Andy Qingan Yuan

Excyte Biopharma Ltd Beijing China

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 May 2017 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
QZQing Zhu
Qing Zhu
JMJason McLellan
Jason McLellan
NKNicole L. Kallewaard
Nicole L. Kallewaard
NUNancy D. Ulbrandt
Nancy D. Ulbrandt
SPSusan Palaszynski
Susan Palaszynski
JSJoAnn A. Suzich
JoAnn A. Suzich
Development of a highly potent anti-RSV monoclonal antibody with extended half-life intended to be used as RSV prophylaxis for all infants.

24 August 2021 in EMBO Molecular Medicine
Verified
Journal Article
Open access
PDF file
SWShuhang Wang
Shuhang Wang
KCKun Chen
Kun Chen
QLQi Lei
Qi Lei
PMPeiwen Ma
Peiwen Ma
AYAndy Qingan Yuan
Andy Qingan Yuan
NLNing Li
Ning Li
Bispecific antibodies (bsAb) that target two independent epitopes or antigens have been extensively explored in translational and clinical studies since they were first developed in the 1960s. Many bsAbs are being tested in clinical trials for treating a variety of diseases, mostly cancer. Here, we provide an overview of various types of bsAbs in clinical studies and discuss their targets, safety profiles, and efficacy. We also highlight the current challenges, potential solutions, and future directions of bsAb development for cancer treatment.